Indication
Ovarian Epithelial Cancer, Stage III
1 clinical trial
2 products
1 drug
Clinical trial
A Phase I Study of a DNA Plasmid Based Vaccine Encoding the HER-2/Neu Intracellular Domain in Subjects With HER-2/Neu (HER2) Overexpressing TumorsStatus: Active (not recruiting), Estimated PCD: 2010-03-01
Product
pNGVL3-hICD vaccineDrug
sargramostimProduct
Protein Expression Analysis